Pretreatment Endoscopy - Pro & Contra: Endoscopy Is Needed before Treatment in All Patients with Gastroesophageal Reflux Disease

Most current endoscopic guidelines do not recommend the use of routine esophagoscopy in the evaluation of patients with typical symptoms of gastroesophageal reflux disease (GERD), unless alarm features are present. In patients with known reflux esophagitis, esophagoscopy is considered to have no role either in the further management or follow-up. Screening of reflux patients for Barrett’s esophagus is not considered to be cost-effective. On the basis of a critical review of the available literature, and of some recent papers in particular, we disagree with these suggestions.
We would argue, on the contrary, that a negative esophagoscopy can provide the GERD patient with reassurance, and that esophagoscopy allows targeted therapy to be offered if it is positive for esophagitis. When Barrett’s esophagus is diagnosed, it usually leads to a surveillance program being initiated. The potential benefits of endoscopy for the patient’s quality of life are probably underestimated when financial issues alone are taken into account. Even if it is true that a large percentage of GERD patients do not have endoscopic abnormalities (those with nonerosive reflux disease), surrogate tests such as the proton-pump inhibitor test or symptom questionnaires do not provide a more accurate diagnosis.
We would therefore suggest that, at least in the specialist setting, all patients with suspected GERD should undergo accurate symptom analysis as well as endoscopic evaluation before treatment is started.

References

• 1 Pace F, Porro G B. Gastroesophageal reflux disease: a typical spectrum disease (a new conceptual framework is not needed).  Am J Gastroenterol. 2004;  99 946-949
• 2 Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis.  Gut. 1991;  32 845-848
• 3 Pace F, Bollani S, Molteni P. et al . Natural history of gastro-oesophageal disease without oesophagitis (NERD): a reappraisal 10 years on.  Dig Liver Dis. 2004;  36 111-115
• 4 Pace F, Bollani S, Manzionna G, Porro G B. Audit of reflux oesophagitis at 4 years.  Ital J Gastroenterol Hepatol. 1998;  30 355-360
• 5 Klauser A G, Schindlbeck N E, Müller-Lissner S A. Symptoms in gastro-oesophageal reflux disease.  Lancet. 1990;  335 205-208
• 6 Dent J, Brun J, Fendrick A M. et al . An evidence-based appraisal of reflux-disease management. The Genval Workshop Report.  Gut. 1999;  44 (Suppl 2) S1-S16
• 7 DeVault K R, Castell D O. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.  Am J Gastroenterol. 1999;  94 1434-1442
• 8 Fennerty M B, Castell D, Fendrick A M. et al . The diagnosis and treatment of GERD in a managed care environment: suggested disease management guidelines.  Arch Intern Med. 1996;  156 477-484
• 9 Baldi F, Crotta S, Penagini R. Guidelines for the diagnostic and therapeutic management of patients with gastro-oesophageal reflux disease: a position statement of the Italian Association of Hospital Gastroenterologists (AIGO), Italian Society of Gastrointestinal Endoscopy (SIED), and Italian Society of Gastroenterology (SIGE).  Ital J Gastroenterol Hepatol. 1998;  30 107-112
• 10 Tytgat G N, Heading R C, Mueller-Lissner S. et al . Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting.  Aliment Pharmacol Ther. 2003;  18 291-301
• 11 DeVault K R, Castell D O. Current diagnosis and treatment of gastroesophageal reflux disease.  Mayo Clin Proc. 1994;  69 867-876
• 12 Rai A, Orlando R. Gastroesophageal reflux disease.  Curr Opin Gastroenterol. 1998;  14 326-333
• 13 Johnson D A, Fennerty M B. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease.  Gastroenterology. 2004;  126 660-664
• 14 Sampliner R E. Updated guidelines for the diagnosis, surveillance and therapy of Barrett’s esophagus.  Am J Gastroenterol. 2002;  97 1888-1895
• 15 Eloubeidi M A, Provenzale D. Clinical and demographic predictors of Barrett’s esophagus among patients with gastroesophageal reflux disease: a multivariate analysis in veterans.  J Clin Gastroenterol. 2001;  33 306-309
• 16 Shaheen N J, Provenzale D, Sandler R S. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence.  Am J Gastroenterol. 2002;  97 1319-1327
• 17 Cooper G S, Yuan Z, Chak A, Rimm A A. Association of prediagnosis endoscopy with stage and survival in adenocarcinoma of the esophagus and gastric cardia.  Cancer. 2002;  95 32-38
• 18 Kearney D J, Crump C, Maynard C, Bokyo E J. A case-control study of endoscopy and mortality from adenocarcinoma of the esophagus and gastric cardia in persons with GERD.  Gastrointest Endosc. 2003;  57 823-829
• 19 Corley D A, Levin T R, Habel L. et al . Association between surveillance and survival in Barrett’s adenocarcinoma: a population-based study.  Gastroenterology. 2002;  122 633-640
• 20 Falk G W. Barrett’s esophagus.  Gastroenterology. 2002;  122 1569-1591
• 21 Mokhashi M S, Wildi S M, Glenn T F. et al . A prospective, blinded study of diagnostic esophagoscopy with a superthin, stand-alone, battery-powered esophagoscope.  Am J Gastroenterol. 2003;  98 2383-2389
• 22 Nietert P J, Silverstein M D, Mokhashi M S. et al . Cost-effectiveness of screening a population with chronic gastroesophageal reflux.  Gastrointest Endosc. 2003;  57 311-318
• 23 Fennerty M B. Extraesophageal gastroesophageal reflux disease: presentations and approach to treatment.  Gastroenterol Clin North Am. 1999;  28 861-874
• 24 Malagelada J R. Supra-oesophageal manifestations of gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2004;  19 (Suppl 1) 43-48
• 25 Moraes-Filho J P, Cecconello I, Gama-Rodrigues . et al . Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management.  Am J Gastroenterol. 2002;  97 241-248
• 26 Dent J. The role of the specialist in the diagnosis and short and long term care of patients with gastroesophageal reflux disease.  Am J Gastroenterol. 2001;  96 (8 Suppl) S22-S26
• 27 Lundell L R, Dent J, Bennett J R. et al . Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification.  Gut. 1999;  45 172-180
• 28 Wallace M B, Durkalski V L, Vaugna J. et al . Age and alarm symptoms do not predict endoscopic findings in patients with dyspepsia: a multicenter database study.  Gut. 2001;  49 29-34
• 29 Numans M E, van der Graaf Y, de Wit N J, de Melker R A. How useful is selection based on alarm symptoms in requesting gastroscopy? An evaluation of diagnostic determinants for gastro-oesophageal malignancy.  Scand J Gastroenterol. 2001;  36 437-443
• 30 Blufstein P K, Beck P L, Meddings J B. et al . The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms.  Am J Gastroenterol. 1998;  93 2508-2512
• 31 Ellis K K, Oehlke M, Helfand M, Liberman D. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management?.  Am J Gastroenterol. 1997;  92 1472-1474
• 32 Turner G, Tham T CK. Does endoscopy alter management for uncomplicated gastroesophageal reflux disease?.  Gastrointest Endosc. 2004;  59 246
• 33 Numans M E, Lau J, de Wit N J, Bonis P A. Short-term treatment with proton pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics.  Ann Intern Med. 2004;  140 518-527
• 34 Irvine E J. Quality of life assessment in gastro-oesophageal reflux disease.  Gut. 2004;  53 (Suppl 4) iv35-iv39
• 35 Luckock M P, Morley S, White C. et al . Responses of consecutive patients to reassurance after gastroscopy: results of a self administered questionnaire survey.  BMJ. 1997;  315 572-575
• 36 Bytzer P, Hansen J M, Schaffalitzky de Muckadell O B. Empirical H₂-blocker therapy or prompt endoscopy in management of dyspepsia.  Lancet. 1994;  343 811-816
• 37 French-Belgian Consensus Conference on Adult Gastro-oesophageal Reflux Disease . “Diagnosis and treatment”: report of a meeting held in Paris, France, on 21 - 22 January 1999. The Jury of the Consensus Conference.  Eur J Gastroenterol Hepatol. 2000;  12 129-137
• 38 Ware J E, Sherbourne C D. The MOS 36 items short form health survey (SF-36): conceptual framework and items selection.  Med Care. 1992;  30 473-483
• 39 Dupuy H J. The psychological general well-being index. In: Wenger NK, Mattson ME, Furberg CF (eds) Assessment of quality of life in trials of cardiovascular therapies. Darien, CT; Le Jacq Communications Inc 1984: 170-183
• 40 EuroQoL Group . EuroQoL: a new facility for the measurement of health-related quality of life.  Health Policy. 1990;  16 199-208
• 41 Svedlund J, Sjodin I, Dotevall G. GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease.  Dig Dis Sci. 1988;  33 129-134
• 42 Locke G R, Talley N J, Weaver A L. et al . A new questionnaire for gastroesophageal reflux disease.  Mayo Clin Proc. 1994;  69 539-547
• 43 Velanovich F V, Vallance S R, Gusz J R. et al . Quality of life scale for gastroesophageal reflux disease.  J Am Coll Surg. 1996;  183 217-224
• 44 Young T L, Kirchdoerfer U, Osterhaus J T. A development and validation process for a disease-specific quality of life instrument.  Drug Inf J. 1996;  30 185-193
• 45 Wiklund I K, Junghard O, Grace E. et al . Quality of life in reflux and dyspepsia patients: psychometric documentation of a new disease-specific questionnaire (QOLRAD).  Eur J Surg Suppl. 1998;  583 41-49
• 46 Eypasch E, Williams J I, Wood-Dauphinee S. et al . Gastrointestinal quality of life index: development, validation and application of a new instrument.  Br J Surg. 1995;  82 216-222